LLY

Eli Lilly & Co
D

LLY

Arincen80/100B

Eli Lilly & Co balance sheet 1985–2026

Eli Lilly & Co had 4.89B USD in cash and short-term investments on 30 September 2026, against total debt of 49.50B USD: net debt of 44.62B USD.

Total assets Total liabilities Shareholders' equity

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
Latest
Q3 FY2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Cash and equivalents
4.89B7.27B3.27B2.82B2.07B3.82B3.66B2.34B7.32B6.54B4.58B
Short-term investments
0.00105.00M154.80M109.10M144.80M90.10M24.20M101.00M88.20M1.50B1.46B
4.89B7.37B3.42B2.93B2.21B3.91B3.68B2.44B7.41B8.03B6.04B
Cash growth
-50.72%+115.38%+16.92%+32.37%-43.41%+6.17%+50.97%-67.09%-7.78%+33.05%+35.64%
Receivables
25.23B20.16B13.28B11.34B8.56B8.13B6.93B5.54B5.78B5.26B4.77B
Inventory
18.19B13.74B7.59B5.77B4.31B3.89B3.98B3.19B3.10B4.46B3.56B
Other current assets
91.00M147.00M111.40M149.50M7.30M0.000.000.002.23B0.000.00
Total current assets
65.26B55.63B32.74B25.73B18.03B18.45B17.46B13.71B20.55B19.20B15.10B
Property, plant and equipment
32.19B24.68B17.10B12.91B10.14B8.99B8.68B8.41B8.00B8.83B8.25B
Long-term investments
4.01B2.80B3.22B3.05B2.90B3.21B2.97B1.96B2.02B5.68B5.21B
Goodwill and intangibles
27.96B12.42B11.94B11.85B11.28B11.58B11.22B10.30B2.43B8.40B8.33B
Goodwill
9.87B5.90B5.77B4.94B4.07B3.89B3.77B3.68B1.37B4.37B3.97B
Intangible assets
18.08B6.52B6.17B6.91B7.21B7.69B7.45B6.62B1.07B4.03B4.36B
Other non-current assets
7.70B6.99B5.72B4.99B4.34B4.08B3.48B2.34B8.30B2.87B1.91B
Total assets
148.07B112.48B78.71B64.01B49.49B48.81B46.63B39.29B43.91B44.98B38.81B
Accounts payable
5.79B5.38B3.23B2.60B1.93B1.67B1.61B1.41B1.21B1.41B1.35B
Deferred revenue
0.000.000.000.000.000.000.000.000.000.000.00
Short-term debt
2.52B1.64B5.12B6.90B1.50B1.54B8.70M1.50B1.10B3.71B1.94B
Other current liabilities
12.22B28.21B7.15B4.93B3.91B10.68B9.30B3.10B3.69B7.82B6.61B
Total current liabilities
47.00B35.23B28.38B27.29B17.14B15.05B12.48B11.78B11.89B14.54B10.99B
Long-term debt
46.99B40.87B28.53B18.32B14.74B15.35B16.59B13.82B9.20B9.93B8.37B
Other non-current liabilities
13.82B9.85B7.54B7.53B6.75B7.52B9.64B8.32B10.60B8.85B5.37B
Lease obligations, current
0.000.000.000.000.000.000.000.000.000.000.00
Lease obligations, long-term
0.000.000.000.000.000.000.00486.70M0.000.000.00
Total liabilities
107.80B85.94B64.44B53.14B38.71B39.65B40.81B36.59B33.00B33.31B24.73B
Common stock and paid-in capital
588.00M590.00M592.40M593.60M594.10M596.30M598.20M598.80M661.00M687.90M688.50M
Retained earnings
37.97B24.47B13.55B10.31B10.04B8.96B7.83B4.92B11.40B13.89B16.05B
Accumulated other comprehensive income
-2.63B-2.88B-4.32B-4.33B-3.84B-4.34B-9.51B-6.52B-8.74B-8.73B-8.29B
Shareholders' equity
40.27B26.54B14.19B10.77B10.65B8.98B5.64B2.61B9.83B11.59B14.01B
Minority interest
0.000.0079.50M91.80M125.60M175.60M183.60M92.20M1.08B75.70M72.80M
49.50B42.50B33.64B25.23B16.24B16.88B16.60B15.80B10.30B13.65B10.31B
Net cash
-44.62B-35.13B-30.22B-22.30B-14.03B-12.98B-12.91B-13.37B-2.89B-5.61B-4.27B
Working capital
18.27B20.40B4.36B-1.57B896.30M3.40B4.98B1.93B8.66B4.67B4.11B
Book value per share
45.0829.5515.7011.9311.779.855.902.729.5111.0212.72
Tangible book value
12.31B14.12B2.26B-1.07B-629.80M-2.60B-5.57B-7.69B7.39B3.19B5.68B
Tangible book value per share
13.7815.722.49-1.19-0.70-2.86-5.83-8.037.153.045.16
Current ratio
1.391.581.150.941.051.231.401.161.731.321.37
Debt to equity
1.231.602.372.341.521.882.946.061.051.180.74

Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

Figures underlined with dots are from the company's SEC filings, where our data provider's differ.

Common questions about Eli Lilly & Co's cash and debt

Source: Financial Modeling Prep